Jim Cramer's 'Mad Money' Recap: Don't Settle For Average

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

NEW YORK (TheStreet) -- Why settle for average when the markets are have so many ways to win? That was Jim Cramer's question to "Mad Money" viewers Thursday as he reviewed some of the market's biggest winners.

Cramer said that while many "experts" still advise just investing in index funds, today's market shows how a little homework can allow investors to do so much better.

Among the day's biggest winners were stocks such as Mylan (MYL), First Solar (FSLR) and Cliffs Natural Resources (CLF). Cramer said that all three of these stocks have terrific prospects and were easily "gettable" during last week's sell off.

Other big winners on the day included Best Buy (BBY), a stock investors could've spotted with a little homework, along with Kohls (KSS) and Sempra Energy (SRE).

Rounding out Cramer's favs were eBay (EBAY), which may bring out value by splitting itself up, Verizon (VZ), which is now a faster growing telco with a terrific 4.5% yield, and Whirlpool (WHR), the appliance maker that both Lowe's (LOW) and Home Depot (HD) told us should do well this quarter.

Don't settle for average, Cramer concluded. There are plenty of great companies with great stories to tell, if you know where to look.

Executive Decision: Aneel Bhusri and Mark Peek

For his "Executive Decision" segment, Cramer spoke with Aneel Bhusri, chairman and co-CEO, and Mark Peek, CFO of Workday (WDAY), the cloud computing purveyor of human resource services that just reported a smaller-than-expected loss, a huge rise in revenue and a 50% increase in its customer base. Shares of Workday are up over 56% since Cramer last checked in back in November.

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

FDA Official Calls for Ending Codeine Use in Kids Cough Products

Will Allergan's Deal With Tribe Hold Up?

Trading Mylan: Look Out for This Key Level

Big Drug Makers Could Face More Pressure on Codeine Remedies for Kids